Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression
IntroductionLymphoma is a prevalent malignant tumor in canines, with chemotherapy as the primary treatment approach. However, chemotherapy indiscriminately targets all rapidly dividing cells, including normal hematopoietic cells, leading to myelosuppression. Recent veterinary practices still lack st...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2025.1635504/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389667680518144 |
|---|---|
| author | Wanbing Pan Wanbing Pan Ruoxi Sun Ruoxi Sun DengShan Shiau Huisheng Xie Jun Dong Jiahao Lin Jiahao Lin |
| author_facet | Wanbing Pan Wanbing Pan Ruoxi Sun Ruoxi Sun DengShan Shiau Huisheng Xie Jun Dong Jiahao Lin Jiahao Lin |
| author_sort | Wanbing Pan |
| collection | DOAJ |
| description | IntroductionLymphoma is a prevalent malignant tumor in canines, with chemotherapy as the primary treatment approach. However, chemotherapy indiscriminately targets all rapidly dividing cells, including normal hematopoietic cells, leading to myelosuppression. Recent veterinary practices still lack standardized and effective management strategies for myelosuppression. This study aimed to evaluate a novel treatment strategy, utilizing the Yang Yin Sheng Xue formula (YYSXF), to alleviate chemotherapy-induced myelosuppression in canines with lymphoma.MethodsA mouse model of myelosuppression was established via intraperitoneal (i.p.) injection of cyclophosphamide (CP, 350 mg/kg). Different concentrations of YYSXF were administered, and peripheral blood cell counts were recorded. Bone marrow nucleated cells (BMNCs), hematopoietic stem cell (HSC) proportions, and apoptosis rates of bone marrow cells (BMCs) were determined. PI staining was performed to investigate YYSXF’s effect on cell cycle progression in the S and G2/M phases of BMCs. Histopathological changes in sternum bone marrow were examined through pathological sections. The outcomes of multicentric lymphoma in 11 canines treated with either CHOP chemotherapy alone or in combination with YYSXF were assessed between April 2021 and April 2022. YYSXF was administered alongside CHOP chemotherapy (Test group, n = 5) to monitor blood cell parameter reduction, and compared with canines receiving only CHOP chemotherapy (Control group, n = 6) to evaluate YYSXF’s efficacy.ResultsYYSXF treatment improved the numbers of peripheral red blood cells (RBCs), white blood cells (WBCs), neutrophils (NEUTs), and platelets (PLTs), while reducing apoptosis and promoting cell cycle progression in bone marrow cells (BMCs) in myelosuppressed mice, however, validation in larger cohorts remains necessary. YYSXF also increased BMNC counts and the percentage of HSCs in BMCs, alleviating reductions in hematopoietic cell counts and fat vacuolation in the bone marrow. In the clinical phase, a decrease in complete blood count (CBC) indicators was observed after the eighth chemotherapy cycle in multicentric lymphoma canines, significantly delaying the onset of chemotherapy-induced reductions (p < 0.05) compared to the Control Group (third chemotherapy cycle).DiscussionThese findings suggest the potential efficacy of YYSXF in supporting bone marrow hematopoiesis in mice, with further validation in canine models needed before clinical application. |
| format | Article |
| id | doaj-art-e4fa9604b76a4d4cbfb38f515086ca8e |
| institution | Kabale University |
| issn | 2297-1769 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj-art-e4fa9604b76a4d4cbfb38f515086ca8e2025-08-20T03:41:53ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692025-08-011210.3389/fvets.2025.16355041635504Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppressionWanbing Pan0Wanbing Pan1Ruoxi Sun2Ruoxi Sun3DengShan Shiau4Huisheng Xie5Jun Dong6Jiahao Lin7Jiahao Lin8State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, ChinaChina Veterinary Medicine Innovation Center, China Agricultural University, Beijing, ChinaState Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, ChinaChina Veterinary Medicine Innovation Center, China Agricultural University, Beijing, ChinaDepartment of Traditional Chinese Veterinary Medicine, Chi University, Reddick, FL, United StatesDepartment of Traditional Chinese Veterinary Medicine, Chi University, Reddick, FL, United StatesChina Agricultural University Veterinary Teaching Hospital, Beijing, ChinaState Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, ChinaChina Veterinary Medicine Innovation Center, China Agricultural University, Beijing, ChinaIntroductionLymphoma is a prevalent malignant tumor in canines, with chemotherapy as the primary treatment approach. However, chemotherapy indiscriminately targets all rapidly dividing cells, including normal hematopoietic cells, leading to myelosuppression. Recent veterinary practices still lack standardized and effective management strategies for myelosuppression. This study aimed to evaluate a novel treatment strategy, utilizing the Yang Yin Sheng Xue formula (YYSXF), to alleviate chemotherapy-induced myelosuppression in canines with lymphoma.MethodsA mouse model of myelosuppression was established via intraperitoneal (i.p.) injection of cyclophosphamide (CP, 350 mg/kg). Different concentrations of YYSXF were administered, and peripheral blood cell counts were recorded. Bone marrow nucleated cells (BMNCs), hematopoietic stem cell (HSC) proportions, and apoptosis rates of bone marrow cells (BMCs) were determined. PI staining was performed to investigate YYSXF’s effect on cell cycle progression in the S and G2/M phases of BMCs. Histopathological changes in sternum bone marrow were examined through pathological sections. The outcomes of multicentric lymphoma in 11 canines treated with either CHOP chemotherapy alone or in combination with YYSXF were assessed between April 2021 and April 2022. YYSXF was administered alongside CHOP chemotherapy (Test group, n = 5) to monitor blood cell parameter reduction, and compared with canines receiving only CHOP chemotherapy (Control group, n = 6) to evaluate YYSXF’s efficacy.ResultsYYSXF treatment improved the numbers of peripheral red blood cells (RBCs), white blood cells (WBCs), neutrophils (NEUTs), and platelets (PLTs), while reducing apoptosis and promoting cell cycle progression in bone marrow cells (BMCs) in myelosuppressed mice, however, validation in larger cohorts remains necessary. YYSXF also increased BMNC counts and the percentage of HSCs in BMCs, alleviating reductions in hematopoietic cell counts and fat vacuolation in the bone marrow. In the clinical phase, a decrease in complete blood count (CBC) indicators was observed after the eighth chemotherapy cycle in multicentric lymphoma canines, significantly delaying the onset of chemotherapy-induced reductions (p < 0.05) compared to the Control Group (third chemotherapy cycle).DiscussionThese findings suggest the potential efficacy of YYSXF in supporting bone marrow hematopoiesis in mice, with further validation in canine models needed before clinical application.https://www.frontiersin.org/articles/10.3389/fvets.2025.1635504/fullmyelosuppressionYang Yin Sheng Xue formulachemotherapycanineadverse effects |
| spellingShingle | Wanbing Pan Wanbing Pan Ruoxi Sun Ruoxi Sun DengShan Shiau Huisheng Xie Jun Dong Jiahao Lin Jiahao Lin Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression Frontiers in Veterinary Science myelosuppression Yang Yin Sheng Xue formula chemotherapy canine adverse effects |
| title | Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression |
| title_full | Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression |
| title_fullStr | Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression |
| title_full_unstemmed | Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression |
| title_short | Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression |
| title_sort | efficacy of yang yin sheng xue formula against canine lymphoma chemotherapy induced myelosuppression |
| topic | myelosuppression Yang Yin Sheng Xue formula chemotherapy canine adverse effects |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2025.1635504/full |
| work_keys_str_mv | AT wanbingpan efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT wanbingpan efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT ruoxisun efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT ruoxisun efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT dengshanshiau efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT huishengxie efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT jundong efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT jiahaolin efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression AT jiahaolin efficacyofyangyinshengxueformulaagainstcaninelymphomachemotherapyinducedmyelosuppression |